anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An embodiment herein provides a local delivery device for targeted therapeutic effect. Accordingly, the local delivery device comprises a cap preferably a hemispherical cap, a locking part and a shaft part, wherein the local delivery device can be of a centre tightened local delivery device or a periphery tightened delivery device, wherein the hemispherical cap comprises a screw driver slot at its centre or at its periphery. The locking part has its outer surface threaded and includes a canister to accommodate the desired agent for delivery or can be made of substance intended with or without additives and bases. The locking part may be attached to the hemispherical cap. The shaft part includes unthreaded or threaded configuration and attached to the locking part. A locking hole provides an aperture to introduce the local delivery device to the plate or other implants of choice and bone underneath..
The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
Composition contains the vascular anticoagulant annexine and/or its natural or synthetic derivatives or analogues, and Ca++, Cd++, Zn++, Mn++, and/or Co++, and optionally adjuvants, carriers and/or stabilisers. The anticoagulant may be produced by gene technology. A 320-amino acid residue and a 327-amino acid residue peptide are specifically claimed. Preferably the composition contains 0.1-100 mM Ca++ and/or 0.1-100 uM Zn++. The product may be freeze dried. It is given topically or by injection. The dose is 0.005-0.1 mg/kg body weight by injection, so a single dose contains 0.4-7.5 mg of anticoagulant. For topical application, the aqueous solution contains 0.1-1.5 mg/10 ml. USE/ADVANTAGE - The product is claimed for the prophylaxis and treatment of thrombosis. The divalent salts are necessary for the binding of certain anticoagulants (e.g. annexine) to phospholipids such as the phosphatidyl serines, allowing membrane-associated effects to occur and inhibiting coagulation.  The addition of the divalent salts allows the anticoagulant to work better in cases of deficienc
PURPOSE:To obtain a carcinostatic agent having low toxicity and sustained and high antitumor action, containing a derivative of betulin, plant derived pentacyclic compound as an active ingredient. CONSTITUTION:A carcinostatic agent containing a compound shown by the formula (R1 and R2 are hydroxyl, <=18C acyl or p-toluenesulfonyloxy but are not simultaneously hydroxyl; R3 is methyl or halo-methyl) as an active ingredient. The compound shown by the formula can be orally or parenterally administered to mammals including human. The parenteral administration is carried out intravenously, through the abdominal cavity or hypodermically. A dose of the carcinostatic agent is 10mg-100mg/time calculated as the active ingredient and administered approximately daily or about 30g/time is preferably administered every 3-7 days. 3,28-Di-acetoxylup-20(29)-ene, etc., may be cited as the compound shown by the formula.
Post-menopausal women with normal bone density (BMD t-score \>-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
Once the radiation plan is ready, you will be brought to the radiation treatment room and positioned for treatment. You will be lying on your back on the treatment table during the radiation treatment. You will not see, hear, or feel the radiation during the treatment. The treatment time varies but may range from 1-3 three hours. Once the treatment is completed, the headframe/mask will be removed and you will be brought to a recovery area.
BACKGROUND: Late-onset sepsis (LOS) and pneumonia are common infectious diseases, with high morbidity and mortality in neonates. This study aimed to investigate the differences in the gut microbiota among preterm infants with LOS, or pneumonia, and full-term infants. Furthermore, this study aimed to determine whether there is a correlation between intestinal pathogenic colonization and LOS.
METHODS: In a single-center case‒control study, 16 S rRNA gene sequencing technology was used to compare gut microbiota characteristics and differences among the LOS group, pneumonia group, and control group.
RESULTS: Our study revealed that the gut microbiota in the control group was more diverse than that in the LOS group and pneumonia group (P < 0.05). No significant differences in diversity were detected between the LOS and pneumonia groups (P > 0.05). Compared with the control group, the abundances of Akkermansia, Escherichia/Shigella, and Enterococcus increased, while the abundances of Bacteroides and Stenotrophomonas decreased in the LOS and pneumonia groups. The pathogenic bacteria in infants with LOS were consistent with the distribution of the main bacteria in the intestinal microbiota. An increase in Escherichia/Shigella abundance may predict a high risk of LOS occurrence, with an area under the curve (AUC) of 0.773.
CONCLUSION: Changes in the gut microbiota composition were associated with an increased risk of LOS and pneumonia. The dominant bacteria in the gut microbiota of the LOS group were found to be associated with the causative pathogen of LOS. Moreover, preterm infants exhibiting an elevated abundance of Escherichia/Shigella may be considered potential candidates for predicting the onset of LOS.
The present invention relates to a technology and equipment for extracting raw materials of traditional Chinese medicine. A condenser (11) and an oil-water separator (13) are connected to an extracting tank (14) through pipelines to form one circulating loop, and a circulation pump (7) is connected through a pipeline to form the other circulation loop. Raw materials of traditional Chinese medicine are contained in a basket (17) and loaded in the extracting tank, and solvent is added. The raw materials are heated by steam for extracting, and medicine liquid is pumped in the extracting tank once again by the circulation pump through the circulation loops for carrying out dynamic circulation extraction. Evaporated essential oil in the raw materials of traditional Chinese medicine is separated through the condenser and the oil-water separator, and the separated solvent is used as new solvent and a heat source, which flows back to the extracting tank through the circulation loops for a next turn of circulation. The previous steps are carried out synchronously for repeated circulation until extraction is finished. The traditional Chinese medicine basket with a gap is arranged in the extracting tank, and the top of the equipment is provided with a top cover which can be opened fully. The present invention has the advantages of high extraction rate, homogeneous extracting liquid, realization of closed and circulated operation of the medicine liquid and full-automatic control, which satisfies the requirement of GMP for medicine production.
All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
Throughout the trial, participants wore a study CGM. Participants spent 5 nights in a supervised outpatient setting using closed-loop control (CLC) system running on DiAs from 23:00 to 07:00. The participants then subsequently had a week at home in which they wore either their personal pump (UVA) or the study pump (Italy) along with a continuous glucose monitor without running in any specialized mathematical equations (sensor-augmented pump therapy or SAP). Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.
Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
INTRODUCTION: Lung transplantation is an effective method for treating end-stage lung disease. It prolongs the survival time of patients, improves the quality of life, and prevents the degree of mental disability. In particular, postoperative cognitive dysfunction (POCD) is one of the complications after lung transplantation. Despite this, longitudinal studies on the identification and heterogeneity of cognitive dysfunction subgroup trajectories in transplant patients are lacking. Therefore, our study aimed to evaluate the factors that influence POCD in lung transplant patients.
METHODS: This prospective longitudinal study included patients who underwent lung transplantation at the transplant center of Wuxi People's Hospital from September 2022 to September 2023. Patients with lung transplants were evaluated at 8 days (T1), 1 month (T2), 3 months (T3), and 6 months (T4) after the operation. The general information questionnaire evaluated cognitive functions using the Montreal Cognitive Assessment (MoCA) numerical rating scale (NRS) and the digital pain assessment to obtain the POCD values. Latent category growth model (LCGM) analysis was used to identify heterogeneous POCD subgroups in the four observation periods. Univariate and logistic regression analyses were used to identify factors affecting POCD classification and independent risk factors.
RESULTS: Based on clinical outcomes, 79 patients completed all four surveys, of whom 16 were lost during the follow-up period (loss rate, 16.8%). The cognitive function by MoCA NRS score was 14.18 ± 5.32 points on day 8 (T1), 22.51 ± 5.13 points at 1 month (T2), 25.44 ± 3.61 at 3 months (T3), and 27.04 ± 3.03 points at 6 months (T4) after lung transplantation, showing an increasing trend. The LCGM, used to fit the trajectory of MoCA scores, observed a heterogeneous trajectory of changes in lung transplant patients. Based on this analysis, patients could be divided into two categories: those with high risk (25,32%) and those with low risk (54,68%). The single-factor analysis identified that POCD values were affected by early postoperative rehabilitation exercise, degree of pain, intensive care unit (ICU) stay time, and donor lung cold ischemia time (all P < 0.05). Using the low-risk group as the reference class, logistic regression analysis showed that the model could correctly classify the subjects.
CONCLUSION: Our 6-month observation of lung transplant patients showed that the degree of cognitive dysfunction had an overall downward trend and that patients could be divided into two trajectories of high and low risk for POCD. Early postoperative rehabilitation exercise, degree of pain, ICU stay time, and donor lung cold ischemia time were all influencing factors for POCD in lung transplant patients.
INTRODUCTION: Chronic pelvic pain (CPP) is a common pain disorder in women associated with negative biopsychosocial consequences. The multifactorial etiology and maintaining aspects of CPP logically require an interprofessional treatment approach. However, the effects of interprofessional treatment strategies on psychosocial factors remain unclear. The study aims to investigate how interprofessional therapy helps to treat psychosocial factors in women with CPP. The systematic review summarizes the current evidence of interprofessional treatment in women with CPP.
MATERIAL AND METHODS: A systematic literature review was performed in six databases (Medline, Web of Science, Cochrane Library, PEDro, CINAHL, and PsycINFO) until February 2023. Studies were selected in a two-step approach applying as inclusion criteria the search combinations of Chronic Pelvic Pain and CPP, synonyms for interprofessional therapies, and for female patients. Studies were excluded if they were not quantitative primary research published in English, if CPP was not defined appropriately, if the study population was not female adult patients, if the interprofessional intervention was not operationalized appropriately, if they were single case studies, and if outcomes did not include at least one of the psychosocial factors pain, depressive symptoms, pain catastrophizing, fear, or anxiety. Risk of bias of the included studies was rated with the McMaster Critical Review Form. Studies were summarized narratively. The review is registered in PROSPERO (CRD42023391008).
RESULTS: Five studies with a total sample size of n = 186 women were included, three of them were uncontrolled retrospective before-after chart review. Only one study used a randomized controlled design, the other study used a non-randomized controlled group. The studies' methodological quality is adequate with perspective of study design. The multiprofessional treatment approaches used in the studies differed with regard to professions involved, therapy methods, and modalities. Psychosocial outcome measures were pain (five studies), depressive symptoms (three studies), and anxiety symptoms (four studies).
CONCLUSIONS: Although interprofessional treatment strategies for women with CPP are recommended in existing guidelines, available evidence is scarce and does not allow for identification of the best interprofessional treatment approach. The effect on psychosocial factors remains unclear. More research is needed determining the best practice interprofessional treatment option for women with CPP.
Because of its carcinogenic properties, chlorambucil should not be given to patients with conditions other than chronic lymphatic leukemia or malignant lymphomas. Convulsions, infertility, leukemia, and secondary malignancies have been observed when chlorambucil was employed in the therapy of malignant and non-malignant diseases.  
  
There are many reports of acute leukemia arising in patients with both malignant and non-malignant diseases following chlorambucil treatment. In many instances, these patients also received other chemotherapeutic agents or some form of radiation therapy. The quantitation of the risk of chlorambucil-induction of leukemia or carcinoma in humans is not possible. Evaluation of published reports of leukemia developing in patients who have received chlorambucil (and other alkylating agents) suggests that the risk of leukemogenesis increases with both chronicity of treatment and large cumulative doses. However, it has proved impossible to define a cumulative dose below which there is no risk of the induction of secondary malignancy. The potential benefits from chlorambucil therapy must be weighed on an individual basis against the possible risk of the induction of a secondary malignancy.  
  
Chlorambucil has been shown to cause chromatid or chromosome damage in humans. Both reversible and permanent sterility have been observed in both sexes receiving chlorambucil.  
  
A high incidence of sterility has been documented when chlorambucil is administered to prepubertal and pubertal males. Prolonged or permanent azoospermia has also been observed in adult males. While most reports of gonadal dysfunction secondary to chlorambucil have related to males, the induction of amenorrhea in females with alkylating agents is well documented and chlorambucil is capable of producing amenorrhea. Autopsy studies of the ovaries from women with malignant lymphoma treated with combination chemotherapy including chlorambucil have shown varying degrees of fibrosis, vasculitis, and depletion of primordial follicles.  
  
Rare instances of skin rash progressing to erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome have been reported. Chlorambucil should be discontinued promptly in patients who develop skin reactions.
This is a study of non-inferiority, multicentre, prospective, randomized into two treatment arms: I) Inspiron ™ stent eluting sirolimus or II) ™ Biomatrix stent eluting biolimus. Are a total of 165 randomized patients.

Patients will be followed for 60 months after the procedure. All new patients will be undergoing angiography for evaluation at 9 months. A subgroup of 60 patients will be evaluated with volumetric intravascular ultrasound at 9 months. Also, a subgroup of 21 patients will be evaluated with optical coherence tomography at the end of the index procedure and 9 months. It is anticipated that the total study duration is 72 months: 12 months to complete the admission of patients and 60 months of follow-up.
An occluder detection system is disclosed. At least one occluder element moves according to a cam motion to apply a periodic compression to a flexible infusion line. A portion of the occluder element is configured to emit or modify an energy or magnetic field. A sensor is configured to measure the energy being emitted or modified by the section of the occluder element. A processor causes the at least one occluder element to move according to the cam motion to move a fluid within the flexible infusion line by periodically compressing the flexible infusion line, measures the energy of the energy source via the sensor, obtains a current cam state associated with the cam motion at a time corresponding to the measured energy, and determines, based on the measured energy and the current cam state, a state of the occluder element. The processor may issue an alarm on a fault condition.
PCT No. PCT/EP95/03135 Sec. 371 Date May 2, 1997 Sec. 102(e) Date May 2, 1997 PCT Filed Aug. 8, 1995 PCT Pub. No. WO96/06114 PCT Pub. Date Feb. 29, 1996The invention relates to adhesion peptides for modifying the adhesion capacity of eukaryotic cells between each other and their use to promote or inhibit the cell/cell adhesion of eukaryotic cells. The invention relates in particular to the use of the cell adhesion polypeptides in the manufacture of pharmaceuticals to influence the cell/cell interactions of eukaryotic cells.
PURPOSE: To obtain a dentifrice composition excellent in property capable of readily breaking capsules in using and capable of recognizing the existence in the oral cavity and free from feeling of physical disorder and feeling of foreign matter by producing the capsules using agar as a main component of a film-forming substance and forming the capsules as proper particle diameter range coinciding with the object. CONSTITUTION: This dentifrice composition contains agar as a main component of film-forming substances and a capsule having 0.3-3mm, especially 0.5-3mm average particle diameter capable of readily being broken by brushing. The dentifrice composition has good feeling to users and good product appearance. The strength of agar jelly is preferably >=500g/cm<2> . The coating ratio of agar to the capsule is preferably 1-30wt.%. The breakage strength of the capsule is preferably 0.1-20g/one capsule. The capsule is preferably produced by a double nozzle dropping method. The transparency of the composition is preferably >=3mm. In the composition, the capsule is readily broken and a pharmacodynamic ingredient, etc., can be released and permeated into an oral cavity by carrying out brushing. The capsule can confirm the existence by sight and gives feeling of security to persons.
Gene fusions represent a distinct class of structural variants identified frequently in cancer genomes across cancer types. Several gene fusions exhibit gain of oncogenic function and thus have been the focus of development of efficient targeted therapies. However, investigation of fusion landscape in early-onset sporadic rectal cancer, a poorly studied colorectal cancer subtype prevalent in developing countries, has not been performed. Here, we present a comprehensive landscape of gene fusions in EOSRC and CRC using patient derived tumor samples and data from The Cancer Genome Atlas, respectively. Gene Ontology analysis revealed enrichment of unique biological process terms associated with 5'- and 3'- fusion partner genes. Extensive network analysis highlighted genes exhibiting significant promiscuity in fusion formation and their association with chromosome fragile sites. Investigation of fusion formation in the context of global chromatin architecture unraveled a novel mode of gene activation that arose from fusion between genes located in orthogonal chromatin compartments. The study provides novel evidence linking fusions to genome stability and architecture and unearthed a hitherto unidentified mode of gene activation in cancer.
Growth differentiation factor 11 (GDF11) belongs to the transforming growth factor beta superfamily and participates in various pathophysiological processes. Initially, GDF11 was suggested to act as a rejuvenator by improving age-related phenotypes of the heart, brain, and skeletal muscle in aged mice. Recent studies demonstrate that GDF11 also serves as an adverse risk factor for human frailty and diseases. However, the role of GDF11 in pulmonary fibrosis (PF) remains unclear. This study explored the role and signaling mechanisms of GDF11 in PF. GDF11 expression was markedly up-regulated in fibrotic lung tissues of both humans and mice. Intratracheal administration of commercial recombinant GDF11 caused lung injury, inflammation, and fibrogenesis in mice. Furthermore, adenovirus-mediated secretory expression of mature GDF11 was exacerbated, whereas full-length GDF11 or the GDF11 propeptide (GDF111-298) alleviated bleomycin-induced PF in mice. In in vitro experiments, GDF11 suppressed the growth of alveolar and bronchial epithelial cells (A549 and BEAS-2B) and human pulmonary microvascular endothelial cells, promoted fibroblast activation, and induced epithelial/endothelial-mesenchymal transition. These effects corresponded to the phosphorylation of Smad2/3, and blocking activin A receptor type II-like kinase, 53kDa (ALK5)-Smad2/3 signaling abolished the in vivo and in vitro effects of GDF11. In conclusion, these findings provide evidence that GDF11 acts as a potent injurious, proinflammatory, and profibrotic factor in the lungs via the ALK5-Smad2/3 pathway.
Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
A composition for stabilising one or more unstable bioactive components is provided, wherein the composition comprises a protective matrix of at least agar and glycerol; and a bioactive component in the range of 0.005-25 % w/w embedded in the matrix. The bioactive component may be an oil component, preferably a marine oil, for example green shell mussel oil, hoki oil, or fish oil, or a combination thereof. The composition may further comprise at least one of sodium chloride, water, rice flour, molasses, ascorbic acid, canola oil, and flavour enhancer, or a combination thereof. A colouring agent selected to prevent penetration of light through the matrix may be included. The composition for use as a medicament, optionally a veterinary medicament is provided. The medicament may be for the treatment or prevention of inflammation, or diseases substantially mediated by inflammatory processes. A method of manufacturing the stable bioactive composition is provided, which may involve the step of shaping and cutting the composition into chews. The composition is preferably in a chew form which may be easier to administer to children, the elderly or companion animals than other oral dosage forms.